
N-Mycin5%
Aristopharma Ltd.
Natamycin ophthalmic suspension is an antifungal medicine used to treat eye infections caused by susceptible fungi.
Natamycin ophthalmic suspension is an antifungal medicine used to treat eye infections caused by susceptible fungi. Its evidence-based uses include:
Natamycin is also used industrially as a food-grade preservative on cheese and cured meat surfaces to inhibit mold growth; this food-preservative use is a separate application from its medical use as an ophthalmic antifungal and is not a use covered by this medicine information.
| Phase | Adult dose |
|---|---|
| Initial therapy | 1 drop of Natamycin ophthalmic suspension instilled into the conjunctival sac every 1-2 hours |
| After 3-4 days | Frequency may be reduced to 1 drop 6-8 times daily |
| Total duration | Usually 14-21 days, or continued until active fungal keratitis has resolved (as judged by the treating ophthalmologist) |
| Tapering | A gradual reduction in dosing over 4-7 day intervals may help confirm elimination of the organism before stopping therapy |
Usually a lower frequency of 4-6 applications of Natamycin ophthalmic suspension per day is adequate; the exact schedule should be individualized by the prescribing physician based on clinical response.
The same dosing principles used in adults are generally applied under specialist ophthalmologic supervision, as a specific pediatric dosing schedule for Natamycin has not been separately established; safety and efficacy in children have not been formally established in controlled trials (see Use in Special Populations).
No dose adjustment is required for renal or hepatic impairment, since Natamycin ophthalmic suspension has negligible systemic absorption after topical ocular use.
The most commonly reported side effects of Natamycin ophthalmic suspension are local and generally mild:
Less commonly, allergic reactions, corneal opacity, or changes in vision have been reported after use of Natamycin; rare systemic reactions such as chest discomfort or difficulty breathing have been reported post-marketing but are not clearly established to be caused by the topical drug given its minimal systemic absorption. Patients should notify their physician if any side effect is severe or persistent.
Natamycin ophthalmic suspension is contraindicated in patients with known hypersensitivity to Natamycin or to any component of the formulation. There are no other well-established absolute contraindications to topical ophthalmic Natamycin.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.